Trials / Completed
CompletedNCT00422890
Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Technische Universität Dresden · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy and safety of 5-Azacytidin in the treatment of the haematological relapse in patients suffering from acute myeloid leukaemia or myelodysplastic syndrome with falling CD34-chimerism after hematopoietic stem cell transplantation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 5-Azacytidin | in case of decreasing CD34 chimerism |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2009-12-01
- First posted
- 2007-01-17
- Last updated
- 2011-07-11
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00422890. Inclusion in this directory is not an endorsement.